Abstract
Currently, no vaccines or therapeutics are licensed to counter Ebola or Marburg viruses, highly pathogenic filoviruses that are causative agents of viral hemorrhagic fever. Here we show that administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30-60 min after infection, protects>60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection. PMOplus may be useful for treating these and other highly pathogenic viruses in humans.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Ebolavirus / isolation & purification
-
Filoviridae Infections / genetics*
-
Filoviridae Infections / immunology
-
Filoviridae Infections / mortality
-
Filoviridae Infections / prevention & control*
-
Hemorrhagic Fever, Ebola / genetics
-
Hemorrhagic Fever, Ebola / immunology
-
Hemorrhagic Fever, Ebola / prevention & control
-
Humans
-
Macaca mulatta / immunology
-
Marburg Virus Disease / genetics
-
Marburg Virus Disease / immunology
-
Marburg Virus Disease / prevention & control
-
Marburgvirus / isolation & purification
-
Primates
-
Safety
-
Vaccines, Synthetic / therapeutic use*
-
Viral Vaccines / therapeutic use*
Substances
-
Vaccines, Synthetic
-
Viral Vaccines